<?xml version='1.0' encoding='utf-8'?>
<document id="29730365"><sentence text="Clustering based drug-drug interaction networks for possible repositioning of drugs against EGFR mutations: Clustering based DDI networks for EGFR mutations." /><sentence text="EGFRs are a vast group of receptor tyrosine kinases playing an important role in a number of tumors, including lungs, head and neck, breast, and esophageal cancers"><entity charOffset="35-43" id="DDI-PubMed.29730365.s2.e0" text="tyrosine" /></sentence><sentence text=" A couple of techniques are being used in the process of drug design" /><sentence text=" Drug repositioning or repurposing is a rising idea that consists of distinguishing modern remedial indications for officially existing dynamic pharmaceutical compounds" /><sentence text=" Here, a novel approach of analyzing drug-drug interaction networks, based on clustering methodology is used to reposition effective compounds against mutant EGFR having G719X, exon 19 deletions/insertions, L858R, and L861Q mutations" /><sentence text=" Data about 2062 drugs are obtained, and mining is performed to filter only those drugs which fulfill Lipinski rule of five" /><sentence text=" Clustering is performed, and DDIs are built on the clusters to identify effective drug compounds" /><sentence text=" Only 1052 compounds fulfill Lipinski rule" /><sentence text=" 12 clusters are formed for 1052 drugs compounds" /><sentence text=" DDIs are developed for each cluster" /><sentence text=" Only 15 drugs are suggested to be more effective assuming strong interactions in a DDI" /><sentence text="" /></document>